Klinische Studien und Therapieoptionen bei Immunneuropathien

Zusammenfassung Immunneuropathien stellen eine äußerst heterogene Gruppe von akut, zum überwiegenden Teil aber chronisch verlaufenden Erkrankungen mit gravierender Morbidität dar, die das periphere Nervensystem in verschiedenen Facetten betreffen. In klinischen Studien konnte die Bedeutung immunmodulierender und -supprimierender Therapiestrategien unterstrichen werden, wobei weiterhin Bedarf zur Entwicklung wirksamerer Therapieoptionen besteht, um diese mit Langzeitbehinderung assoziierten Erkrankungen besser behandeln zu können.

[1]  R. Hughes,et al.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. , 2017, The Cochrane database of systematic reviews.

[2]  H. Hartung,et al.  The clinical value of therapeutic plasma exchange in multifocal motor neuropathy , 2008, Journal of the Neurological Sciences.

[3]  H. Hartung,et al.  Immunneuropathien - Von der Pathogenese zur Therapie , 2008 .

[4]  W. Paulus,et al.  Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy , 2008, Muscle & nerve.

[5]  L. H. van den Berg,et al.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. , 2007, Brain : a journal of neurology.

[6]  H. Hartung,et al.  From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve , 2007, Nature Clinical Practice Neurology.

[7]  H. Hartung,et al.  The inflamed peripheral nervous system: update on immune therapies , 2006, Current opinion in neurology.

[8]  R. Gold,et al.  Therapy of immune neuropathies with intravenous immunoglobulins , 2006, Journal of Neurology.

[9]  H. Hartung,et al.  Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases , 2006, Muscle & nerve.

[10]  H. Hartung,et al.  Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies , 2006, Journal of Neurology.

[11]  H. Hartung,et al.  Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. , 2006, Archives of neurology.

[12]  J. Browning.  B cells move to centre stage: novel opportunities for autoimmune disease treatment , 2006, Nature Reviews Drug Discovery.

[13]  R. Sakakibara,et al.  Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H) , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  R. Hughes,et al.  Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  G. Deuschl,et al.  High-dose rituximab and anti-MAG–associated polyneuropathy , 2006, Neurology.

[16]  A. Visudtibhan,et al.  Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. , 2005, Pediatric neurology.

[17]  G. Lauria,et al.  Worsening after rituximab treatment in anti‐mag neuropathy , 2005, Muscle & nerve.

[18]  A. Priori,et al.  Multifocal motor neuropathy: Current concepts and controversies , 2005, Muscle & nerve.

[19]  H. Hartung,et al.  Chronic inflammatory demyelinating polyneuropathy – update on pathogenesis, diagnostic criteria and therapy , 2005, Current opinion in neurology.

[20]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[21]  A. Pestronk,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. , 2005, Archives of neurology.

[22]  P. Fuhr,et al.  Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg , 2004, Neurology.

[23]  A. Ropper,et al.  Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy , 2004, Neurology.

[24]  H. Hartung,et al.  Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system , 2004, Muscle & nerve.

[25]  N. Latov.  Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2004, Neurology.

[26]  E. Frohman,et al.  Mycophenolate Mofetil in Multiple Sclerosis , 2004, Clinical neuropharmacology.

[27]  J. Meulstee,et al.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial , 2004, The Lancet.

[28]  R. Hughes,et al.  A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome , 2003, Neurology.

[29]  G. Deuschl,et al.  Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies , 2003, Muscle & nerve.

[30]  H. Hartung,et al.  Immune mechanisms in chronic inflammatory demyelinating neuropathy , 2002, Neurology.

[31]  R. Hughes,et al.  Immunosuppressive treatment for multifocal motor neuropathy. , 2002, The Cochrane database of systematic reviews.

[32]  G. Comi,et al.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.

[33]  K. Hirata,et al.  Clinical features and response to treatment in Guillain‐Barré syndrome associated with antibodies to GM1b ganglioside , 2000, Annals of neurology.

[34]  W. Bradley,et al.  The spectrum of chronic inflammatory demyelinating polyneuropathy , 2000, Journal of the Neurological Sciences.

[35]  MD Jean-Claude Raphael,et al.  Appropriate number of plasma exchanges in Guillain‐Barré syndrome , 1997, Annals of neurology.

[36]  L. Visser,et al.  Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome , 1996, Annals of neurology.

[37]  C Chalk,et al.  Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. , 1996, Brain : a journal of neurology.

[38]  T. Crawford,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[39]  Guillain-Barré Syndrome Study Group.  Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome , 1993, The Lancet.

[40]  A. Pestronk,et al.  Immunosuppressive treatment in multifocal motor neuropathy , 1991, Annals of neurology.

[41]  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) , 1991, Neurology.

[42]  J. Daube,et al.  Combined azathioprine and prednisone in chronic inflammatory‐demyelinating polyneuropathy , 1985, Neurology.

[43]  J. Albers,et al.  Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy , 1985, Muscle & nerve.

[44]  I. Husstedt,et al.  HIV-assoziierte Neuropathien , 2008, Nervenheilkunde.

[45]  A. Engelhardt.  Immunvermittelte Polyneuropathien , 2007, Nervenheilkunde.

[46]  R. Gold,et al.  Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues , 2007, Nature Clinical Practice Neurology.

[47]  C. Koski.  Initial and Long-Term Management of Autoimmune Neuropathies , 2005, CNS drugs.